CLAIMS:

1. The use of a compound of Formula (I),



Formula (I)

wherein:

$\mathbf{R^1}$ is selected from: hydrogen, optionally substituted C_{1-6}alkyl, optionally substituted aryl or optionally substituted arylC_{1-6}alkyl, wherein the optional substituents are selected from C_{1-4}alkyl, nitro, cyano, fluoro and C_{1-4}alkoxy;

$\mathbf{R^2}$ is an optionally substituted mono or bi-cyclic aromatic ring, wherein the optional substituents are 1, 2 or 3 subsituents independently selected from: cyano, $\mathbf{R^eR^f}$N-, C_{1-6}alkyl, C_{1-6}alkoxy, halo, haloC_{1-6}alkyl or haloC_{1-6}alkoxy wherein $\mathbf{R^e}$ and $\mathbf{R^f}$ are independently selected from hydrogen, C_{1-6}alkyl or aryl;

$\mathbf{R^3}$ is selected from a group of Formula (IIa) to Formula (IId):



Formula (IIa)



Formula (IIb)



Formula (IIc)



Formula (IId)

where $\mathbf{R^6}$ and $\mathbf{R^{6a}}$ are independently selected from hydrogen, fluoro, optionally substituted C_{1-6}alkyl, C_{1-6}alkoxy, or $\mathbf{R^6}$ and $\mathbf{R^{6a}}$ taken together and the carbon atom to which they are attached form a carbocyclic ring of 3-7 atoms or $\mathbf{R^6}$ and $\mathbf{R^{6a}}$ taken together and the carbon atom to which they are attached form a carbonyl group;

or when **A** is not a direct bond the group  forms a carbocyclic ring of 3-7 carbon atoms or a heterocyclic ring containing one or more heteroatoms;

or the group  forms a heterocyclic ring containing 3-7 carbon atoms and one or more heteroatoms;

R^7 is selected from: hydrogen or C_{1-6}alkyl;

R^8 is selected from:

(i) hydrogen, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, haloC_{1-6}alkyl, C_{1-4}alkoxyC_{1-4}alkyl, hydroxy, hydroxyC_{1-6}alkyl, cyano, N-C_{1-4}alkylamino, N,N-di-C_{1-4}alkylamino, C_{1-6}alkyl–S(O_n)-, -O-**R**^{b}, –N**R**^{b}**R**^{c}, –C(O)-**R**^{b}, –C(O)O-**R**^{b}, -CON**R**^{b}**R**^{c}, NH-C(O)-**R**^{b} or –S(O_n)N**R**^{b}**R**^{c},
where **R**^{b} and **R**^{c} are independently selected from hydrogen and C_{1-6}alkyl optionally substituted with hydroxy, amino, N-C_{1-4}alkylamino, N,N-di-C_{1-4}alkylamino, HO-C_{2-4}alkyl-NH- or HO-C_{2-4}alkyl-N(C_{1-4}alkyl)-;

(ii) nitro when **B** is a group of Formula (IV) and **X** is CH and **p** is 0;

(iii) carbocyclyl (such as C_{3-7}cycloalkyl or aryl) or arylC_{1-6}alkyl each of which is optionally substituted by **R**^{12}, or **R**^{13};

(iv) heterocyclyl or heterocyclylC_{1-6}alkyl each of which is optionally substituted by up to 4 substituents independently selected from **R**^{12} or **R**^{13}, and where any nitrogen atoms within a heterocyclyl group are, where chemically allowed, optionally in their oxidised (N→O, N-OH) state;

A is selected from:

(i) a direct bond;

(ii) optionally substituted C_{1-5}alkylene wherein the optional substituents are independently selected from: hydroxy, hydroxyC_{1-6}alkyl, C_{1-6}alkyl, C_{1-6}alkoxy, C_{1-4}alkoxyC_{1-4}alkyl, aryl or arylC_{1-6}alkyl;

(iii) a carbocyclic ring of 3-7 atoms;

(iv) a carbonyl group or –C(O)–C(**R**^{d}**R**^{d})-, wherein **R**^{d} is independently selected from hydrogen and C_{1-2}alkyl;

or when $\mathbf{R^3}$ is a group of Formula (IIa) or (IIb), the group  forms a heterocyclic ring containing 3-7 carbon atoms and one or more heteroatoms;

or when $\mathbf{R^3}$ is a group of Formula (IIa), (IIb), (IIc) or (IId), the group  forms a heterocyclic ring containing 3-7 carbon atoms and one or more heteroatoms;

B is selected from:

(i) a direct bond;

(ii) a group of Formula (IV)



Formula (IV)

wherein:

X is selected from N or CH,

wherein at position (a) Formula (IV) is attached to the nitrogen atom and the $(CH_2)_p$ group is attached to $\mathbf{R^8}$; and

(iii) a group independently selected from: optionally substituted C_{1-6}alkylene, optionally substituted C_{3-7}cycloalkyl, optionally substituted C_{3-6}alkenylene, optionally substituted C_{3-6}alkynyl, $(C_{1-5}alkyl)_{aa}$-$S(O_n)$-$(C_{1-5}alkyl)_{bb}$-, -$(C_{1-5}alkyl)_{aa}$-O-$(C_{1-5}alkyl)_{bb}$-, -$(C_{1-5}alkyl)_{aa}$-C(O)-$(C_{1-5}alkyl)_{bb}$- or $(C_{1-5}alkyl)_{aa}$-N($\mathbf{R^{17}}$)- $(C_{1-5}alkyl)_{bb}$, or -$(C_{1-5}alkyl)_{aa}$-C(O)NH-$(C_{1-5}alkyl)_{bb}$-

where $\mathbf{R^{17}}$ is hydrogen or C_{1-4}alkyl, or where $\mathbf{R^{17}}$ and the $(C_{1-5}alkyl)_{aa}$ or $(C_{1-5}alkyl)_{bb}$ chain can be joined to form a heterocyclic ring, wherein aa and bb are independently 0 or 1 and the combined length of $(C_{1-5}alkyl)_{aa}$ and $(C_{1-5}alkyl)_{bb}$ is less than or equal to C_5alkyl and wherein the optional substituents are independently selected from $\mathbf{R^{12}}$;

or the group –**B**-$\mathbf{R^8}$ represents a group of Formula (V)



Formula (V);



or the group together forms an optionally substituted heterocyclic ring containing 4-7 carbons atoms, wherein the optional substituents are selected from 1 or 2 substituents independently selected from $\mathbf{R^{12}}$ and $\mathbf{R^{13}}$;



or the group forms a heterocyclic ring containing 3-7 carbon atoms and one or more heteroatoms;

$\mathbf{R^{11}}$ is selected from: hydrogen, optionally substituted C_{1-6}alkyl, $N(\mathbf{R^{23}R^{24}})$ or $NC(O)O\mathbf{R^{25}}$, where $\mathbf{R^{23}}$, $\mathbf{R^{24}}$ and $\mathbf{R^{25}}$ are independently selected from: hydrogen, hydroxy, optionally substituted C_{1-6}alkyl, optionally substituted aryl, optionally substituted arylC_{1-6}alkyl, an optionally substituted carbocyclic ring of 3-7 atoms, optionally substituted heterocyclyl or optionally substituted heterocyclylC_{1-6}alkyl or $\mathbf{R^{23}}$ and $\mathbf{R^{24}}$ taken together with the nitrogen atom to which they are attached, can form an optionally substituted ring of 3-10 atoms,

wherein the optional substituents are selected from $\mathbf{R^{12}}$ and  where K and R^8 are as defined herein;

J is a group of the formula: $-(CH_2)_s$-**L**-$(CH_2)_s$- or $-(CH_2)_s$-C(O)-$(CH_2)_s$-**L**-$(CH_2)_s$-wherein when **s** is greater than 0, the alkylene group is optionally substituted,



or the group together forms an optionally substituted heterocyclic ring containing 4-7 carbons atoms, wherein the optional substituents are selected from 1 or 2 substituents independently selected from $\mathbf{R^{12}}$ and $\mathbf{R^{13}}$;

K is selected from: a direct bond, $-(CH_2)_{s1}$-, $-(CH_2)_{s1}$-O-$(CH_2)_{s2}$-, $-(CH_2)_{s1}$-C(O)-$(CH_2)_{s2}$-, $-(CH_2)_{s1}$-$S(O_n)$-$(CH_2)_{s2}$-, $-(CH_2)_{s1}$-$N(\mathbf{R^{17a}})$-$(CH_2)_{s2}$-, $-(CH_2)_{s1}$-$C(O)N(\mathbf{R^{17a}})$-$(CH_2)_{s2}$-, $-(CH_2)_{s1}$-$N(\mathbf{R^{17a}})C(O)$-$(CH_2)_{s2}$-, $-(CH_2)_{s1}$-$N(\mathbf{R^{17a}})C(O)N(\mathbf{R^{17a}})$-$(CH_2)_{s2}$-, $-(CH_2)_{s1}$-OC(O)-$(CH_2)_{s2}$-, $-(CH_2)_{s1}$-C(O)O-$(CH_2)_{s2}$-, $-(CH_2)_{s1}$-$N(\mathbf{R^{17a}})C(O)O$-$(CH_2)_{s2}$-, $-(CH_2)_{s1}$-$OC(O)N(\mathbf{R^{17a}})$-$(CH_2)_{s2}$-, $-(CH_2)_{s1}$-$OS(O_n)$-$(CH_2)_{s2}$-, or $-(CH_2)_{s1}$-$S(O_n)$-O-$(CH_2)_{s2}$-,

$-(CH_2)_{s1}-S(O)_2N(\mathbf{R}^{17a})-(CH_2)_{s2}-$or $-(CH_2)_{s1}-N(\mathbf{R}^{17a})S(O)_2-(CH_2)_{s2}-$; wherein the $-(CH_2)_{s1}-$ and $-(CH_2)_{s2}-$ groups are independently optionally substituted by hydroxy or C_{1-4}alkyl and wherein when s1>1 or s2>1 then the CH_2 group can optionally be a branched chain.;

where $\mathbf{R}^{17a}$ is hydrogen or C_{1-4}alkyl;

L is selected from optionally substituted aryl or optionally substituted heterocyclyl;

$\mathbf{R}^4$ is selected from hydrogen, C_{1-4}alkyl or halo;

$\mathbf{R}^5$ is selected from a group of Formula **III-a**; **III-b**; **III-c**; **III-d**; **III-e; III-f, III-g , III-h,** **III-i**, or **III-j**, **III-k**, **III-l**, **III-m**, **III-n** or **III-o**



III-a



III-b



III-c



III-d



III-e



III-f



III-g



III-h



III-i



III-j



III-k



III-l



III-m



III-n



III-o

wherein:

het represents an optionally substituted 3- to 8-membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from O, N and S,

wherein the optional substituents are selected from 1-2 groups selected from $\mathbf{R^{12}}$ and $\mathbf{R^{13}}$; and

Q is selected from a direct bond or $-[C(\mathbf{R^{16}R^{16a}})]_{1\text{-}2}$-;

$\mathbf{R^{14}}$ and $\mathbf{R^{15}}$ are selected from:

(i) $\mathbf{R^{14}}$ selected from hydrogen; optionally substituted $C_{1\text{-}8}$alkyl; optionally substituted aryl; -$\mathbf{R^{d}}$-Ar, where $\mathbf{R^{d}}$ represents $C_{1\text{-}8}$alkylene and Ar represents optionally substituted aryl; and optionally substituted 3- to 8-membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S; and $\mathbf{R^{15}}$ is selected from hydrogen; optionally substituted $C_{1\text{-}8}$alkyl and optionally substituted aryl;

(ii) wherein the group of Formula (III) represents a group of Formula **III-a , III-b**, **III-i**, **III-l** or **III-m**, then the group $N\mathbf{R^{14}}(-\mathbf{R^{15}})$ represents an optionally substituted 3- to 8-membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S; or

(iii) wherein the group of Formula (III) represents structure **III-e**, 

represents an optionally substituted 3- to 8-membered heterocyclic ring optionally containing from 1 to 4 heteroatoms independently selected from O, N and S;

$\mathbf{R^{16}}$ and $\mathbf{R^{16a}}$ are independently selected from:

(i) hydrogen or optionally substituted $C_{1\text{-}8}$alkyl; or

(ii) $\mathbf{R^{16}}$ and $\mathbf{R^{16a}}$ together with the carbon to which they are attached form an optionally substituted 3 to 7-membered cycloalkyl ring;

$\mathbf{R^{12}}$ is independently selected from: halo, hydroxy, hydroxy$C_{1\text{-}6}$alkyl, oxo, cyano, cyano$C_{1\text{-}6}$alkyl, nitro, carboxyl, $C_{1\text{-}6}$alkyl, $C_{1\text{-}6}$alkoxy, $C_{1\text{-}6}$alkoxy$C_{1\text{-}4}$alkyl, $C_{1\text{-}6}$alkoxycarbonyl$C_{0\text{-}4}$alkyl, $C_{1\text{-}6}$alkanoyl$C_{0\text{-}4}$alkyl, $C_{1\text{-}6}$alkanoyloxy$C_{0\text{-}4}$alkyl, $C_{2\text{-}6}$alkenyl, $C_{1\text{-}3}$perfluoroalkyl-, $C_{1\text{-}3}$perfluoroalkoxy, aryl, aryl$C_{1\text{-}6}$alkyl, heterocyclyl, heterocyclyl$C_{1\text{-}6}$alkyl, amino$C_{0\text{-}4}$alkyl, N-$C_{1\text{-}4}$alkylamino$C_{0\text{-}4}$alkyl, N, N-di-$C_{1\text{-}4}$alkylamino$C_{0\text{-}4}$alkyl, carbamoyl, N-$C_{1\text{-}4}$alkylcarbamoyl$C_{0\text{-}2}$alkyl, N, N-di-$C_{1\text{-}4}$alkylaminocarbamoyl$C_{0\text{-}2}$alkyl, aminocarbonyl$C_{0\text{-}4}$alkyl, N-$C_{1\text{-}6}$alkyaminocarbonyl$C_{0\text{-}4}$alkyl, N, N-$C_{1\text{-}6}$alkyaminocarbonyl$C_{0\text{-}4}$alkyl, $C_{1\text{-}6}$alkyl-$S(O)_n$-amino$C_{0\text{-}4}$alkyl-, aryl-$S(O)_n$-amino$C_{0\text{-}2}$alkyl-, $C_{1\text{-}3}$perfluoroalkyl-$S(O)_n$-amino$C_{0\text{-}2}$alkyl-; $C_{1\text{-}6}$alkylamino-$S(O)_n$-$C_{0\text{-}2}$alkyl-,

arylamino-S(O)$_n$-C$_{0-2}$alkyl-, C$_{1-3}$perfluoroalkylamino-S(O)$_n$-C$_{0-2}$alkyl-, C$_{1-6}$alkanoylamino-S(O)$_n$-C$_{0-2}$alkyl-; arylcarbonylamino-S(O)$_n$-C$_{0-2}$alkyl-, C$_{1-6}$alkyl-S(O)$_n$-C$_{0-2}$alkyl-, aryl-S(O)$_n$-C$_{0-2}$alkyl- , C$_{1-3}$perfluoroalkyl-, C$_{1-3}$perfluoroalkoxyC$_{0-2}$alkyl; $\mathbf{R^{9'}}$OC(O)(CH$_2$)$_w$-, $\mathbf{R^{9''}R^{10''}}$N(CH$_2$)$_w$-, $\mathbf{R^{9'}R^{10'}}$NC(O)(CH$_2$)$_w$-, $\mathbf{R^9R^{10}}$NC(O)N($\mathbf{R^9}$)(CH$_2$)$_w$-, $\mathbf{R^9}$OC(O)N($\mathbf{R^9}$)(CH$_2$)$_w$-, or halo, wherein **w** is an integer between 0 and 4 and $\mathbf{R^9}$ and $\mathbf{R^{10}}$ are independently selected from hydrogen, C$_{1-4}$alkyl, C$_{1-4}$alkylsulphonyl and C$_{3-7}$carbocyclyl, $\mathbf{R^{9'}}$ and $\mathbf{R^{10'}}$ are independently selected from C$_{1-4}$alkylsulphonyl and C$_{3-7}$carbocyclyl, and $\mathbf{R^{9''}}$ and $\mathbf{R^{10''}}$ are C$_{3-7}$carbocyclyl; wherein an amino group within $\mathbf{R^{12}}$ is optionally substituted by C$_{1-4}$alkyl;

$\mathbf{R^{13}}$ is C$_{1-4}$alkylaminocarbonyl wherein the alkyl group is optionally substituted by 1, 2 or 3 groups selected from $\mathbf{R^{12}}$, **or** $\mathbf{R^{13}}$ is a group –C(O)-$\mathbf{R^{18}}$ and $\mathbf{R^{18}}$ is selected from an amino acid derivative or an amide of an amino acid derivative;

M is selected from –CH$_2$-CH$_2$- or –CH=CH-;

n is an integer from 0 to 2;

p is an integer from 0 to 4;

s, s1 and **s2** are independently selected from an integer from 0 to 4, and

s1+**s2** is less than or equal to 4;

t is an integer between 0 and 4; and

or a salt, solvate or pro-drug thereof, in the manufacture of a medicament for

(a) antagonising gonadotropin releasing hormone activity;

(b) administration to a patient, for reducing the secretion of luteinizing hormone by the pituitary gland of the patient; and

(c) administration to a patient, for therapeutically treating and/or preventing a sex hormone related condition in the patient.

2. A compound of formula (IA) which is a compound of formula (I) as defined in claim 1, with the proviso that when

(i) the group 

forms an aromatic carbocyclic ring of 3-7 carbon atoms or an aromatic heterocyclic ring containing one or more heteroatoms, or

(ii) when $\mathbf{R^3}$ is a group of Formula (IIa) or (IIb), and the group  forms an aromatic heterocyclic ring containing 3-7 carbon atoms and one or more heteroatoms; or

(iii) when $\mathbf{R^3}$ is a group of Formula (IIa), (IIb), (IIc) or (IId), and the group

 forms an aromatic heterocyclic ring containing 3-7 carbon atoms and one or more heteroatoms, or



(iv) when the group forms an aromatic heterocyclic ring containing 3-7 carbon atoms and one or more heteroatoms and A is a direct bond;

then $\mathbf{R^5}$ is other than a group III-o.

3. A compound according to claim 2 wherein the group **A** is selected from (i) a direct bond or (ii) optionally substituted C_{1-5}alkylene wherein the optional substituents are independently selected from: hydroxy, hydroxyC_{1-6}alkyl, C_{1-6}alkyl, C_{1-6}alkoxy, C_{1-4}alkoxyC_{1-4}alkyl, aryl or arylC_{1-6}alkyl.

4. A compound according to claim 2 or claim 3 which includes a group $\mathbf{R^{13}}$ and wherein the group $\mathbf{R^{13}}$ is –C(O)-$\mathbf{R^{18}}$, and $\mathbf{R^{18}}$ is selected from an amino acid derivative or an amide of an amino acid derivative; or a salt, solvate or pro-drug thereof.

5. A compound according to any one of claims 2 to 4 wherein $\mathbf{R^1}$ is selected from hydrogen, optionally substituted C_{1-6}alkyl or optionally substituted arylC_{1-6}alkyl, wherein the optional substitutuents are selected from: fluoro and C_{1-4}alkoxy.

6. A compound according to any one of claims 2 to 5 wherein $\mathbf{R^2}$ is phenyl, optionally susbstituted by one or more groups selected from methyl, ethyl, methoxy, ethoxy, *tert*-butoxy, F or Cl.

7. A compound according to any one of claims 2 to 6 wherein $\mathbf{R^3}$ is selected from a group of formula (IIc) or formula (IId).

8. A compound according to any one of claims 2 to 7 wherein $\mathbf{R^4}$ is selected from hydrogen, methyl, ethyl, chloro or bromo.

9. A compound according to any one of claims 2 to 8 wherein $\mathbf{R^5}$ is selected from a group of Formula **III-a** , **III-g**, **III-h**, **III-i**, **III-j**, **III-k** , **III-l**: or **III-o**



III-a



III-g



III-h



III-i



III-j



III-k



III-l



III-o

wherein $\mathbf{R^{16}}$, $\mathbf{R^{16a}}$, $\mathbf{R^{14}}$ and $\mathbf{R^{15}}$ are as defined in claim 1.

10. A compound according to claim 9 wherein R^5 is a group of formula



11. A compound according to any one of claims 2 to 10 wherein **M** is $-CH_2-CH_2-$.

12. A compound of Formula (Ia)



Formula (Ia)

wherein:

R^3 is selected from a group of Formula (IIa) or Formula (IIb):



Formula (IIa)



Formula (IIb)

R^7 is selected from: hydrogen or C_{1-6}alkyl;

B is a group of Formula (IV)



Formula (IV)

and p, **A**, X, **M**, **R^1**, **R^2**, **R^4**, **R^5** **R^6**, **R^{6a}**, **R^8**, and **R^{11}** are as defined above for a compound of Formula (I)

or a salt, solvate or pro-drug thereof.

13. A compound of Formula (Ic)



Formula (Ic)

wherein:

R^3 is selected from a group of Formula (IIc) or Formula (IId):



Formula (IIc)



Formula (IId)

wherein

the group  together forms an optionally substituted heterocyclic ring containing 4-7 carbons atoms, wherein the optional substituents are selected from 1 or 2 substituents independently selected from $\mathbf{R^{12}}$ and $\mathbf{R^{13}}$;

and **A**, **M**, **J**, $\mathbf{R^1}$, $\mathbf{R^2}$, $\mathbf{R^4}$, $\mathbf{R^5}$ $\mathbf{R^6}$, $\mathbf{R^{6a}}$, $\mathbf{R^8}$, and $\mathbf{R^{12}}$ and $\mathbf{R^{13}}$ are as defined in claim 1,

or a salt, solvate or pro-drug thereof.

14. A compound selected from:

3-[3,3-Dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[2-{4-(morpholin-4-ylcarbonyl)piperidin-1-yl}ethyl]-5-(3,5-dimethylphenyl)-1H-pyrrole;

3-[3,3-dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)but-2-en-1-yl]-4-[1s-methyl-2-(n'-isopropoxycarbonyl-3-pyrid-4-yl-pyrrolidin-1-ylcarboximidamido) ethyl]-5-(3,5-dimethylphenyl)-1h-pyrrole;

3-[3,3-Dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[1S-methyl-2-(N'-isopropoxycarbonyl-3-pyrid-4-yl-pyrrolidin-1-ylcarboximidamido) ethyl]-5-(3,5-dimethylphenyl)-1H-pyrrole;

3-[3,3-Dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[2-{4-(pyrrolidin-1-ylcarbonyl)piperazin-1-yl}ethyl]-5-(3,5-dimethylphenyl)-1H-pyrrole;

2-chloro-3-[3,3-dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[2-{4-(pyrrolidin-1-ylcarbonyl)piperazin-1-yl}ethyl]-5-(3,5-dimethylphenyl)-1h-pyrrole;

3-[3,3-dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[2-{4-(4-hydroxypiperidin-1-ylcarbonyl)piperidin-1-yl}ethyl]-5-(3,5-dimethylphenyl)-1h-pyrrole;

3-[3,3-dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[2-{4-(1,1-dioxo-isothiazolidin-2-ylcarbonyl)-4-methoxy-piperidin-1-yl}ethyl]-5-(3,5-dimethylphenyl)-1h-pyrrole;

3-[3,3-dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[1s-methyl-2-{1-benzyl-pyrrodin-3-ylamino}ethyl]-5-(3,5-dimethylphenyl)-1h-pyrrole;

3-[3,3-dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[1s-methyl-2-(2-{4-n-isopropylureidophenyl}ethylamino)ethyl]-5-(3,5-dimethylphenyl)-1h-pyrrole;

3-[3,3-dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[1s-methyl-2-{4-(pyrid-4-yl)piperidin-1-ylcarbonylamino}ethyl]-5-(3,5-dimethylphenyl)-1h-pyrrole;

3-[3,3-dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[1s-methyl-2-{3-(pyrid-4-yl)ppyrrolidin-1-ylcarbonylamino}ethyl]-5-(3,5-dimethylphenyl)-1h-pyrrole; and

3-[3,3-dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[1s-methyl-2-{4-phenylpiperidin-1-ylcarbonylamino}ethyl]-5-(3,5-dimethylphenyl)-1h-pyrrole.

15. A process for preparing a compound of formula (I) as defined in claim 1, or a compound according to any one of claims 2 to 14, said process comprising a step selected from (a) to (h):

(a) reaction of a compound of formula **XXXII** with a compound of formula H-$\mathbf{R^{3'}}$,



XXXII

wherein $\mathbf{X^1}$ is selected from:  and  ; $\mathbf{L^1}$ is a displaceable group; and

$\mathbf{H\text{-}R^{3'}}$ is selected from:  ,  and  ;

(b) reaction of a compound of formula **XXXIII** with a compound of formula $\mathbf{L^2\text{-}R^{3''}}$,



Formula (IIc)



Formula (IId)

wherein

the group  together forms an optionally substituted heterocyclic ring containing 4-7 carbons atoms, wherein the optional substituents are selected from 1 or 2 substituents independently selected from R^{12} and R^{13};

and **A**, **M**, **J**, R^1, R^2, R^4, R^5 R^6, R^{6a}; R^8, and R^{12} and R^{13} are as defined in claim 1,

or a salt, solvate or pro-drug thereof.

14. A compound selected from:

3-[3,3-Dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[2-{4-(morpholin-4-ylcarbonyl)piperidin-1-yl}ethyl]-5-(3,5-dimethylphenyl)-1H-pyrrole;

3-[3,3-dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)but-2-en-1-yl]-4-[1s-methyl-2-(n'-isopropoxycarbonyl-3-pyrid-4-yl-pyrrolidin-1-ylcarboximidamido) ethyl]-5-(3,5-dimethylphenyl)-1h-pyrrole;

3-[3,3-Dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[1S-methyl-2-(N'-isopropoxycarbonyl-3-pyrid-4-yl-pyrrolidin-1-ylcarboximidamido) ethyl]-5-(3,5-dimethylphenyl)-1H-pyrrole;

3-[3,3-Dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[2-{4-(pyrrolidin-1-ylcarbonyl)piperazin-1-yl}ethyl]-5-(3,5-dimethylphenyl)-1H-pyrrole;

2-chloro-3-[3,3-dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[2-{4-(pyrrolidin-1-ylcarbonyl)piperazin-1-yl}ethyl]-5-(3,5-dimethylphenyl)-1h-pyrrole;

3-[3,3-dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[2-{4-(4-hydroxypiperidin-1-ylcarbonyl)piperidin-1-yl}ethyl]-5-(3,5-dimethylphenyl)-1h-pyrrole;

3-[3,3-dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[2-{4-(1,1-dioxo-isothiazolidin-2-ylcarbonyl)-4-methoxy-piperidin-1-yl}ethyl]-5-(3,5-dimethylphenyl)-1h-pyrrole;

3-[3,3-dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[1s-methyl-2-{1-benzyl-pyrrodin-3-ylamino}ethyl]-5-(3,5-dimethylphenyl)-1h-pyrrole;

3-[3,3-dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[1s-methyl-2-(2-{4-n-isopropylureidophenyl}ethylamino)ethyl]-5-(3,5-dimethylphenyl)-1h-pyrrole;

3-[3,3-dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[1s-methyl-2-{4-(pyrid-4-yl)piperidin-1-ylcarbonylamino}ethyl]-5-(3,5-dimethylphenyl)-1h-pyrrole;

3-[3,3-dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[1s-methyl-2-{3-(pyrid-4-yl)ppyrrolidin-1-ylcarbonylamino}ethyl]-5-(3,5-dimethylphenyl)-1h-pyrrole; and

3-[3,3-dimethyl-4-oxo-4-(azabicyclo[2.2.1]heptan-7-yl)butyl]-4-[1s-methyl-2-{4-phenylpiperidin-1-ylcarbonylamino}ethyl]-5-(3,5-dimethylphenyl)-1h-pyrrole.

15. A process for preparing a compound of formula (I) as defined in claim 1, or a compound according to any one of claims 2 to 14, said process comprising a step selected from (a) to (h):

(a) reaction of a compound of formula **XXXII** with a compound of formula H-$\mathbf{R^{3'}}$,



XXXII

wherein $\mathbf{X^1}$ is selected from:  and  ; $\mathbf{L^1}$ is a displaceable group; and

$\mathbf{H\text{-}R^{3'}}$ is selected from:  ,  and  ;

(b) reaction of a compound of formula **XXXIII** with a compound of formula $\mathbf{L^2\text{-}R^{3''}}$,



XXXIII



and



wherein X^2 is selected from: ; L^2 is a displaceable group and R^{7a} is selected from the definition of R^7 or R^{22} above, and

L^2-$R^{3"}$ is selected from: $L^2—B—R^8$, $L^2—J—K—R^8$ and $L^2—R^{21}$

(c) for compounds of Formula (I) or (IA) wherein R^7 is other than part of a heterocyclic ring or hydrogen, reaction of a compound of Formula (I) or (IA) wherein R^3 is a group of Formula (IIa), (IIb), (IIc) or (IId) and R^7 is hydrogen with a group of formula L^3-R^{7a}, wherein R^{7a} is as defined above for R^7 with the exclusion of hydrogen and L^3 is a displaceable group;

(d) for compounds of Formula (I) or (IA) wherein R^4 is hydrogen, reduction of a thienopyrrole of Formula XXXVIII



XXXVII

(e) for compounds of Formula (I) wherein R^3 is a group of Formula (IIc) or (IId) and



the group together forms an optionally substituted nitrogen-containing heterocyclic ring containing 4-7 carbons atoms, reaction of a compound of Formula **XXXIVa** or **XXXIVb**, with a compound of Formula L^6-K-R^8, wherein L^6 is a displaceable group



XXXIVa



XXXIVb

(f) for compounds of Formula (I) wherein $\mathbf{R^3}$ is a group of Formula (IIc) or (IId), reaction of a compound of Formula **XXXVa** or **XXXVb**, with a compound of Formula $\mathbf{L^7}$-**K''**-$\mathbf{R^8}$, wherein $\mathbf{L^7}$ is a displaceable group, and wherein the groups **K'** and **K''** comprise groups which when reacted together form **K**,



XXXVa



XXXVb ;

(g) reaction of a compound of Formula **XXXVI** with an electrophillic compound of the formula $\mathbf{L^8}$-$\mathbf{R^3}$, wherein $\mathbf{L^8}$ is a displaceable group



XXXVI

(h) reaction of a compound of Formula XXXIX with an appropriate electrophilic reagent to give a compounds of Formula (I)



XXXIX

and thereafter if necessary, carrying out one or more of the following steps:

i) converting a compound of the Formula (I) into another compound of the Formula (I);

ii) removing any protecting groups;

iii) forming a salt, pro-drug or solvate.

16. A pharmaceutical formulation comprising a compound according to any one of claims 2 to 14, or salt, pro-drug or solvate thereof, and a pharmaceutically acceptable diluent or carrier.

17. A method of antagonising gonadotropin releasing hormone activity in a patient, comprising administering a compound of formula (I) or (IA), or salt, pro-drug or solvate thereof, to a patient.

18. A compound according to any one of claims 2 to 14 for use as a medicament.